Barclays Remains a Buy on Merck & Company (MRK)

In a report released today, Emily Field from Barclays maintained a Buy rating on Merck & Company, with a price target of $140.00.

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Field covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and Cytokinetics. According to TipRanks, Field has an average return of 1.4% and a 42.94% success rate on recommended stocks.

In addition to Barclays, Merck & Company also received a Buy from Rothschild & Co Redburn’s Natalya Davies in a report issued on April 17. However, on April 15, Morgan Stanley maintained a Hold rating on Merck & Company (NYSE: MRK).

Based on Merck & Company’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $16.4 billion and a net profit of $2.96 billion. In comparison, last year the company earned a revenue of $15.62 billion and had a net profit of $3.74 billion

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year. Most recently, in February 2026, Chirfi Guindo, the CMO of MRK sold 10,000.00 shares for a total of $1,214,500.00.